← Leaderboards
Shruti H Mehta
Johns Hopkins University
$41,677,787
Attributed
$64,347,667
Total exposure
12
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.6M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$64,347,667 · 12
By mechanism
R01$43,840,879 · 7
U01$17,302,808 · 1
T32$1,888,582 · 1
R56$832,913 · 1
U24$400,898 · 1
F31$81,587 · 1
Top collaborators
- Gregory M Lucas16 shared
- Gregory D Kirk7 shared
- Sunil Suhas Solomon6 shared
- David L Thomas5 shared
- Pamina Mae Gorbach1 shared
- Suzanne M. Siminski1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- David L Thomas$44,227,388
- Gregory M Lucas$25,457,285
- Yvonne Commodore-Mensah$3,406,626
- Philippa Musoke$9,335,883
- Estelle B. Gauda$5,876,566
Others in their field
Top investigators on “Incidence”
- Lawrence Corey · Fred Hutchinson Cancer Center$280,538,218
- David M Nathan · Massachusetts Institute Of Technology$138,375,637
- Sharon A Nachman · Johns Hopkins University$135,132,510
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$127,753,192
- James E. Gern · University Of Wisconsin-Madison$123,967,847
- John M Lachin · George Washington University$118,672,444
Research focus
IncidenceInjecting Drug UserCommunitiesCaringPersonsHiv InfectionsHepatitis CCohortMedicalDrug UsageFutureLinkHepatitis C VirusPharmaceutical PreparationsFollow-UpAcquired Immunodeficiency SyndromeEpidemicBaseCitiesEpidemiologyPrevalenceAids PreventionSuccessHiv Seropositivity
Grant awards (68)
AIDS Linked to the IntraVenous Experience (ALIVE) Study$2,378,750
U01 · FY2025 · DA · contact PI
Johns Hopkins HIV Epidemiology and Prevention Sciences Training Program$527,075
T32 · FY2025 · AI · contact PI
PWID Opportunities to Improve TrEat and Retain (POINTER)$465,879
R01 · FY2025 · DA
PWID Opportunities to Improve TrEat and Retain (POINTER)$401,856
R01 · FY2025 · DA
AIDS Linked to the IntraVenous Experience (ALIVE)$2,436,595
U01 · FY2024 · DA · contact PI
Integrating HCV services into HIV programs for PWID in India$1,071,509
R01 · FY2024 · AI · contact PI
PWID Opportunities to Improve TrEat and Retain (POINTER)$991,640
R01 · FY2024 · DA
Johns Hopkins HIV Epidemiology and Prevention Sciences Training Program$498,297
T32 · FY2024 · AI · contact PI
AIDS Linked to the IntraVenous Experience (ALIVE)$2,437,098
U01 · FY2023 · DA · contact PI
PWID Opportunities to Improve TrEat and Retain (POINTER)$1,060,610
R01 · FY2023 · DA
Integrating HCV services into HIV programs for PWID in India$907,120
R01 · FY2023 · AI · contact PI
Elimination of HCV and related liver disease among HIV-infected and -uninfected people who inject drugs$687,581
R01 · FY2023 · DA
Johns Hopkins HIV Epidemiology and Prevention Sciences Training Program$438,490
T32 · FY2023 · AI · contact PI
AIDS Linked to the IntraVenous Experience (ALIVE)$2,480,863
U01 · FY2022 · DA · contact PI
Integrating HCV services into HIV programs for PWID in India$1,061,654
R01 · FY2022 · AI · contact PI
PWID Opportunities to Improve TrEat and Retain (POINTER)$1,043,280
R01 · FY2022 · DA
Elimination of HCV and related liver disease among HIV-infected and -uninfected people who inject drugs$687,760
R01 · FY2022 · DA
Johns Hopkins HIV Epidemiology and Prevention Sciences Training Program$424,720
T32 · FY2022 · AI · contact PI
AIDS Linked to the IntraVenous Experience (ALIVE)$2,493,073
U01 · FY2021 · DA · contact PI
Strategies to improve the HIV care continuum among key populations in India$1,264,017
R01 · FY2021 · DA
Integrating HCV services into HIV programs for PWID in India$1,144,204
R01 · FY2021 · AI · contact PI
Elimination of HCV and related liver disease among HIV-infected and -uninfected people who inject drugs$664,100
R01 · FY2021 · DA
Collaborating Consortium of Cohorts Producing NIDA Opportunities (C3PNO)$400,898
U24 · FY2021 · DA
AIDS Linked to the IntraVenous Experience (ALIVE)$2,521,954
U01 · FY2020 · DA · contact PI
Strategies to improve the HIV care continuum among key populations in India$1,413,255
R01 · FY2020 · DA
Integrating HCV services into HIV programs for PWID in India$1,123,856
R01 · FY2020 · AI · contact PI
PWID Opportunities to Improve TrEat and Retain (POINTER)$864,464
R01 · FY2020 · DA
Elimination of HCV and related liver disease among HIV-infected and -uninfected people who inject drugs$708,571
R01 · FY2020 · DA
AIDS Linked to the IntraVenous Experience (ALIVE)$2,554,475
U01 · FY2019 · DA · contact PI
Integrating HCV services into HIV programs for PWID in India$899,435
R01 · FY2019 · AI · contact PI
Elimination of HCV and related liver disease among HIV-infected and -uninfected people who inject drugs$727,804
R01 · FY2019 · DA
Strategies to improve the HIV care continuum among key populations in India$1,422,171
R01 · FY2018 · DA
Strategies to improve the HIV care continuum among key populations in India$1,424,389
R01 · FY2017 · DA
INCIDENCE OF HIV INFECTION IN A COHORT OF IV DRUG USERS$1,213,726
R01 · FY2017 · DA · contact PI
INCIDENCE OF HIV INFECTION IN A COHORT OF IV DRUG USERS$1,250,722
R01 · FY2016 · DA · contact PI
INCIDENCE OF HIV INFECTION IN A COHORT OF IV DRUG USERS$1,226,902
R01 · FY2015 · DA · contact PI
Strategies to improve the HIV care continuum among key populations in India$1,169,991
R01 · FY2015 · DA
Integrated Care Clinics for IDUs in India: a cluster randomized trial$1,068,055
R01 · FY2015 · DA
HIV, HCV and Liver Disease Among Injection Drug Users in Chennai, India$522,913
R01 · FY2015 · DA · contact PI
Integrated Care Clinics for IDUs in India: a cluster randomized trial$1,537,931
R01 · FY2014 · DA
INCIDENCE OF HIV INFECTION IN A COHORT OF IV DRUG USERS$1,142,174
R01 · FY2014 · DA · contact PI
HIV, HCV and Liver Disease Among Injection Drug Users in Chennai, India$544,567
R01 · FY2014 · DA · contact PI
Integrated Care Clinics for IDUs in India: a cluster randomized trial$1,302,274
R01 · FY2013 · DA
INCIDENCE OF HIV INFECTION IN A COHORT OF IV DRUG USERS$832,913
R56 · FY2013 · DA · contact PI
HIV, HCV and Liver Disease Among Injection Drug Users in Chennai, India$539,422
R01 · FY2013 · DA · contact PI
INCIDENCE OF HIV INFECTION IN A COHORT OF IV DRUG USERS$195,063
R01 · FY2013 · DA · contact PI
Integrated Care Clinics for IDUs in India: a cluster randomized trial$1,279,936
R01 · FY2012 · DA
Incidence of HIV Infection in a Cohort of IV Drug Users$1,002,081
R01 · FY2012 · DA · contact PI
HIV, HCV and Liver Disease Among Injection Drug Users in Chennai, India$580,907
R01 · FY2012 · DA · contact PI
Integrated Care Clinics for IDUs in India: a cluster randomized trial$1,109,080
R01 · FY2011 · DA
Incidence of HIV Infection in a Cohort of IV Drug Users$1,036,759
R01 · FY2011 · DA · contact PI
Incidence of HIV Infection in a Cohort of IV Drug Users$1,233,803
R01 · FY2010 · DA · contact PI
HIV, HCV and Liver Disease Among Injection Drug Users in Chennai, India$631,218
R01 · FY2010 · DA · contact PI
Incidence of HIV Infection in a Cohort of IV Drug Users$1,090,420
R01 · FY2009 · DA · contact PI
Incidence of HIV Infection in a Cohort of IV Drug Users$150,000
R01 · FY2009 · DA · contact PI
Incidence of HIV Infection in a Cohort of IV Drug Users$22,845
R01 · FY2009 · DA · contact PI
Incidence of HIV Infection in a Cohort of IV Drug Users$652,800
R01 · FY2008 · DA · contact PI
Incidence of HIV Infection in a Cohort of IV Drug Users$163,967
R01 · FY2008 · DA · contact PI
INCIDENCE OF HIV INFECTION IN A COHORT OF IV DRUG USERS$548,692
R01 · FY2007 · DA · contact PI
INCIDENCE OF HIV INFECTION IN A COHORT OF IV DRUG USERS$116,960
R01 · FY2007 · DA · contact PI
INCIDENCE OF HIV INFECTION IN A COHORT OF IV DRUG USERS$610,551
R01 · FY2006 · DA · contact PI
INCIDENCE OF HIV INFECTION IN A COHORT OF IV DRUG USERS$591,879
R01 · FY2005 · DA
INCIDENCE OF HIV INFECTION IN A COHORT OF IV DRUG USERS$59,587
R01 · FY2005 · DA
INCIDENCE OF HIV INFECTION IN A COHORT OF IV DRUG USERS$595,967
R01 · FY2004 · DA
INCIDENCE OF HIV INFECTION IN A COHORT OF IV DRUG USERS$614,532
R01 · FY2003 · DA
HEPATITIS C INFECTION &DIABETES IN INJECTION DRUG USERS$10,336
F31 · FY2002 · DA
HEPATITIS C INFECTION &DIABETES IN INJECTION DRUG USERS$36,600
F31 · FY2001 · DA
HEPATITIS C INFECTION &DIABETES IN INJECTION DRUG USERS$34,651
F31 · FY2000 · DA